Overview of CAR T Cell Immunotherapy
Introduction to CAR T Cell Therapy
A recent review published in the journal Science highlights the achievements and challenges associated with a groundbreaking immunotherapy employing CAR T cells for cancer treatment. The immune system plays a crucial role in identifying and destroying cancer cells within the body, with effector T cells being particularly significant in targeting these malignant cells.
Mechanism of Action
Recent advancements have enabled scientists and engineers to develop complex cell receptors that initiate robust anti-cancer responses. The process of adoptive T cell therapies involves drawing blood from patients, isolating their T cells, engineering these cells to express new receptors, and then reinfusing them into the patient.
Understanding CAR T Cells
Definition and Function
One specific engineered T-cell receptor is known as the chimeric antigen receptor (CAR), leading to the therapy referred to as CAR T-cell therapy. These CAR T cells are designed to target a specific antigen with high potency. For instance, in B cell lymphomas and leukemia, these cancer cells express the CD19 marker, which can be targeted by CD19 CAR T cells.
Clinical Success
Numerous clinical studies have reported remarkable outcomes with CAR T therapy, including an early trial where cancer cells were eradicated in 90% of patients. Consequently, the U.S. Food and Drug Administration (FDA) has approved this treatment for patients with B-cell cancers. Research is ongoing to identify additional cancer targets, aiming to extend this therapy’s application to melanomas, renal cancers, and lung cancers.
Challenges and Risks
Specificity and Off-Target Effects
The success of CD19 CAR T cells can be attributed to their specificity for a unique subset of cells. However, many other cancers lack such precise markers, or their markers are shared with normal cells. While CAR T cells exhibit potent activity, they can also induce significant toxicities due to heightened immune stimulation and inflammation, particularly in trials targeting less specific molecules.
Managing Risks
The potential for off-target effects raises concerns about serious neurologic complications, although some can be managed. Thus, maintaining a balance between the potency and safety of CAR T cell therapy is essential for researchers and clinicians. To mitigate risks, CARs can be engineered to adjust the affinity of the receptor for its target, and technologies exist to integrate a “suicide switch” into engineered T cells, allowing for their selective elimination after fulfilling their function.
Future Directions and Implications
Current Research Landscape
The novel CAR T cell therapy has shown significant promise, with over 250 clinical trials currently underway globally, predominantly in the United States and China. There is a substantial financial incentive to refine this therapy for various cancers, particularly chronic types where patients often receive lifelong, albeit non-curative, treatments.
Cost and Accessibility
Currently, the production of adoptive T cell therapies is quite expensive; however, costs are anticipated to decline as manufacturing processes improve. More models are needed to assess the safety and efficacy of CAR T cells before widespread implementation across different cancer types can occur.
Conclusion
Nonetheless, advancements in cellular engineering are expected to propel CAR T cell therapy forward, potentially revolutionizing cancer treatment methodologies.
References
Written by Branson Chen, BHSc
Reference: June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018 Mar 23;359(6382):1361-5.
Related Topics of Interest
– Is heart stem cell therapy possible?
– Myelin in neural stem cell therapy may help repair spinal cord injuries
– CAR T cell therapy for cancer
– Can Stem Cell Therapy Cure Epidermolysis Bullosa?
– Stem Cell Therapy: A Lethal Cure
– Cell Therapy for Stroke Treatment